MID ATLANTIC PROSTATE CANCER BANK

前列腺癌是我们这个时代最大的医学挑战之一。在美国，它的绝对发病率排名第一，仅次于肺癌，成为男性癌症死亡的原因之一。直肠指诊和血清前列腺特异性抗原筛查(PSA)的日益常规使用扩大了公众对前列腺癌的认识、诊断和接受前列腺癌治疗的男性数量。这是在分子病理学的进步为研究人员提供了更多的癌症研究机会的时候。然而，加强前列腺癌研究的关键是这种恶性肿瘤及其相应的良性和正常对应的标本的现成可用。这项建议的主要目标是开发一个全面的、用户友好的、最先进的银行，其中包含保存最好的前列腺癌、上皮内前列腺癌以及良性和正常前列腺组织和生物(血液、尿液等)的样本。标本及其相应的临床数据，以协助将基础研究转化为临床应用。具体目标是：建立中大西洋前列腺癌银行(MAPCB)，由有能力和有兴趣共同努力的机构组成，以实现NCI合作前列腺癌组织资源(资源)的创建和目标；建立和维护一个全面的高质量固定和冷冻的癌症、良性和正常前列腺癌标本以及其他相关细胞和液体标本以及相关临床数据的数据库；建立一个质量保证系统，以监测收集和保存过程，并确保收集和分发给个别调查人员的材料的质量；建立一个行政结构，以维护患者的机密性，同时向调查人员提供关于标本和相应临床数据的准确信息；审查与前列腺癌有关的新研究，以保持保存样本的相关性；并与NCI和其他获奖者合作，宣传资源，优化(和标准化)样本和临床数据收集、保存、质量控制和分发流程和政策。这一资源将确保研究人员将为他们的研究获得具有临床和病理相关性的最佳研究标本。

Prostate cancer is one of the great medical challenges of our time. It stands first in absolute incidence and second only to lung cancer as a cause of cancer mortality among men in the United States. The increasingly routine use of digital rectal examination and serum prostate-specific antigen screening (PSA) has magnified public awareness, diagnosis, and the number of men undergoing treatment for prostate cancer. This comes at a time when advances in molecular pathology provide researchers expanding opportunities for the study of cancer. However, critical to enhancing research on prostate cancer is the ready availability of specimens of this malignancy and its corresponding benign and normal counterparts. The principal goal of this proposal is to develop a comprehensive, user- friendly, state-of-the-art bank containing optimally preserved specimens of prostate cancer, intraepithelial prostate neoplasms, and benign and normal prostate tissues and biological (blood, urine, etc.) specimens plus their corresponding clinical data in order to assist in the translation of basic research into clinical applications. The specific aims are to: establish a Mid- Atlantic Prostate Cancer Bank (MAPCB) comprised of institutions capable of and interested in working together toward the creation and goals of the NCI Cooperative Prostate Cancer Tissue Resource (Resource); establish and maintain a comprehensive bank of quality fixed and frozen specimens of cancerous, benign and normal prostate and other relevant cell and fluid specimens accompanied by pertinent clinical data; establish a quality assurance system to monitor the collection and preservation processes and ensure the quality of the material collected and distributed to individual investigators; establish an administrative structure to maintain patients' confidentiality while providing investigators accurate information regarding specimens and corresponding clinical data; review emerging research regarding prostate cancer to maintain relevance of banked specimens; and collaborate with the NCI and other awardees to publicize the Resource, optimize (and standardize) specimen and clinical data collection, preservation, quality control, and distribution processes and policies. This resource will assure that investigators will obtain optimal research specimens with clinical-pathologic correlation for their studies.